PASADENA, Calif. - (Business Wire) Calhoun Vision, Inc., a privately held medical device company engaged in developing and commercializing novel light-adjustable materials technology in the field of ophthalmology, today announced that Gordon H. Busenbark has joined the Company as Chief Financial Officer and Head of Business Development. Mr. Busenbark brings more than 25 years of experience in the pharmaceutical, biotechnology and medical devices industries. Mr. Busenbark joins Calhoun after serving as Chief Financial Officer at Xytis Pharmaceuticals. Prior to Xytis, he was Chief Financial Officer of Encysive Pharmaceuticals, where he was responsible for raising in excess of $100 million in debt and equity financing. Mr. Busenbark started his career with Baxter Healthcare. During 23 years with the company, he held a number of senior-level financial, operational and general management positions in both the U.S. and Europe. These included the roles of Chief Financial Officer of Austria-based Immuno AG, when the company was acquired by Baxter, and President of Baxter’s global Plasma Therapeutics business.
“We are delighted to have Gordon join the Calhoun team. His extensive background and experience will be of great value to the company during this exciting time in our history,” said D. Verne Sharma, CEO and President of Calhoun Vision. “We are making strong progress in our business priorities and Gordon’s financial acumen and management expertise will be valuable in all aspects of our business, including the expansion of our commercial presence in markets outside the U.S.”
Mr. Busenbark holds a Bachelor of Science in Accounting and a Master of Business Administration from the University of Utah in Salt Lake City.
About Calhoun Vision
Using proprietary light adjustable materials technology, Calhoun’s mission is to develop and commercialize products that deliver optimal vision in patients undergoing cataract surgery or clear lens exchange surgery to correct presbyopia. Calhoun has developed, and is selling in markets outside the United States, a light adjustable intraocular lens (“LAL”). The company believes the LAL will revolutionize the cataract and refractive surgery businesses worldwide. Calhoun’s unique LAL technology allows the eye surgeon to change the power of the lens, after it has been implanted, to give the patient either far or near distance acuity or a combination thereof. Calhoun’s LAL is manufactured using a proprietary photosensitive silicone material, which when exposed to a low intensity beam of light, allows the surgeon to precisely change the power of the LAL. The light used for the treatment is generated, controlled and delivered to the eye using a machine specially designed for this application. Calhoun has received regulatory approval for the LAL system in Europe, and the first sales occurred in Germany in 2008. The Company is currently in Phase II FDA clinical trials for the LAL system in the U.S.
For additional information, please visit the Company’s website at www.calhounvision.com.
Calhoun Vision
Gemma Cunningham, 949-637-4296
gemma949@yahoo.com
